Your browser doesn't support javascript.
loading
Development and multicenter validation of an LC-MS-based bioanalytical method for antisense therapeutics.
Sun, Yuchen; Nitta, Shin-Ichiro; Saito, Kosuke; Hosogai, Ryuta; Nakai, Keiko; Goda, Ryoya; Shimizu, Hisao; Fujita, Hisashi; Kakehi, Masaaki; Murata, Kazuyuki; Yamaguchi, Takeru; Okuzono, Takeshi; Yamane, Shinichi; Kawabata, Mitsuhiko; Matsunuma, Takayuki; Takahara, Kentaro; Kato, Noriko; Yamada, Masaki; Yoshida, Tokuyuki; Inoue, Takao; Saito, Yoshiro.
Affiliation
  • Sun Y; Division of Medicinal Safety Science, National Institute of Health Sciences, Kanagawa, 210-9501, Japan.
  • Nitta SI; LSI Medience Corporation, Tokyo, 105-0023, Japan.
  • Saito K; Division of Medicinal Safety Science, National Institute of Health Sciences, Kanagawa, 210-9501, Japan.
  • Hosogai R; LSI Medience Corporation, Tokyo, 105-0023, Japan.
  • Nakai K; LSI Medience Corporation, Tokyo, 105-0023, Japan.
  • Goda R; Daiichi Sankyo Company Ltd, Tokyo, 140-8710, Japan.
  • Shimizu H; Takeda Pharmaceutical Company Ltd, Kanagawa, 251-8555, Japan.
  • Fujita H; Takeda Pharmaceutical Company Ltd, Kanagawa, 251-8555, Japan.
  • Kakehi M; Takeda Pharmaceutical Company Ltd, Kanagawa, 251-8555, Japan.
  • Murata K; Sumika Chemical Analysis Service Ltd, Osaka, 554-0022, Japan.
  • Yamaguchi T; Sumika Chemical Analysis Service Ltd, Osaka, 554-0022, Japan.
  • Okuzono T; Sekisui Medical Co. Ltd, Tokyo, 103-0027, Japan.
  • Yamane S; Sekisui Medical Co. Ltd, Tokyo, 103-0027, Japan.
  • Kawabata M; Shin Nippon Biomedical Laboratories Ltd, Tokyo, 104-0044, Japan.
  • Matsunuma T; Thermo Fisher Scientific KK, Kanagawa, 221-0022, Japan.
  • Takahara K; Thermo Fisher Scientific KK, Kanagawa, 221-0022, Japan.
  • Kato N; Shimadzu Corporation, Kyoto, 140-8710, Japan.
  • Yamada M; Shimadzu Corporation, Kyoto, 140-8710, Japan.
  • Yoshida T; Division of Molecular Target & Gene Therapy Products, National Institute of Health Sciences, Kanagawa, 210-9501, Japan.
  • Inoue T; Division of Molecular Target & Gene Therapy Products, National Institute of Health Sciences, Kanagawa, 210-9501, Japan.
  • Saito Y; Division of Medicinal Safety Science, National Institute of Health Sciences, Kanagawa, 210-9501, Japan.
Bioanalysis ; 14(18): 1213-1227, 2022 Sep.
Article in En | MEDLINE | ID: mdl-36408704
ABSTRACT

Background:

Many bioanalytical methods for antisense oligonucleotides (ASOs) using LC-MS have been reported. However, no data have been available on the reproducibility and robustness of a single bioanalytical method for ASOs. As such, in the current study, we evaluated the reproducibility and robustness of LC-MS-based bioanalytical methods for ASOs in multiple laboratories. Methods/

Results:

Seven independent laboratories were included in this study. Mipomersen was measured by ion-pairing LC-MS (IP-LC-MS) as a model ASO using different LC-MS. The validation results of calibration curve, accuracy, precision and selectivity met the criteria of conventional bioanalytical method validation guidelines using LC/GC-MS for drugs in all laboratories. Meanwhile, carryover (>20%) was detected in three laboratories.

Conclusion:

We first demonstrated the multicenter-validated IP-LC-MS bioanalytical method for ASOs. Our data showed that the method was sensitive, robust and reproducible. However, the occurrence of carryover should be carefully monitored in its future application.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Biological Therapy / Tandem Mass Spectrometry Type of study: Clinical_trials / Prognostic_studies Language: En Journal: Bioanalysis Year: 2022 Type: Article Affiliation country: Japan

Full text: 1 Database: MEDLINE Main subject: Biological Therapy / Tandem Mass Spectrometry Type of study: Clinical_trials / Prognostic_studies Language: En Journal: Bioanalysis Year: 2022 Type: Article Affiliation country: Japan